Cargando…
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at well tolerated doses. However, primary or, less often, secondary resistance to DAs may be also encountered representing challeng...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957547/ https://www.ncbi.nlm.nih.gov/pubmed/31522358 http://dx.doi.org/10.1007/s11102-019-00987-3 |